General Pharmacogenomics

Following is a digest of pharmacogenomics journal articles pertaining to general pharmacogenomics or genomic medicine. The SNP•its editorial team selects articles for inclusion based on clinical relevance and scientific validity. Journal articles that are most readily applicable and relevant to practicing clinicians are selected for a SNP•its Study Summary, which discusses findings and clinical implications of a pharmacogenomics study in the context of the larger evidence base.

Article Citation & LinkTypeMonthSNP•its Study Summary
Delaney SK et al. Direct-to-consumer genetic testing: Perspectives on its value in healthcare. Clin Pharmacol Ther. 2016;99:146-8.Perspective2016-02
Direct-to-consumer genetic testing: a revised position statement of the American College of Medical Genetics and Genomics. Genet Med. 2016;18:207-8.Position Statement2016-02
Flaten HK et al. CYP2C19 drug-drug and drug-gene interactions in ED patients. Am J Emerg Med. 2016;34:245-9.Prospective Observational2016-02
Veenstra DL. The value of routine pharmacogenomic screening—Are we there yet? Clin Pharmacol Ther. 2016;99:164-6.Perspective2016-02
Abaji R, Krajinovic M. Current perspective on pediatric pharmacogenomics. Expert Opin Drug Metab Toxicol. 2016 Feb 15 [Epub ahead of print].Perspective2016-02
Hocum BT et al. Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. Am J Health Syst Pharm. 2016;73:61-7.Retrospective Analysis2016-01
Berm EJ et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. PLoS One. 2016;11:e0146262.Systematic Review2016-01
Weitzel KW et al. The IGNITE network: a model for genomic medicine implementation and research. BMC Med Genomics. 2016;9:1.Descriptive2016-01
O'Donnell PH et al. The outlier in all of us: why implementing pharmacogenomics could matter for everyone. Clin Pharmacol Ther. 2016 Jan 12 [Epub ahead of print].Commentary2016-01
Collins SL et al. Advances in the pharmacogenomics of adverse drug reactions. Drug Saf. 2016;39:15-27.Review2016-01
Chang JS et al. Evaluation of popular drug information resources on clinically useful and actionable pharmacogenomics information. J Med Libr Assoc. 2016;104:58-61.Descriptive2016-01
Roden DM et al. Integrating electronic health record genotype and phenotype datasets to transform patient care. Clin Pharmacol Ther. 2016;99:298-305.Review2016-01
Unertl KM et al. Clinician perspectives on using pharmacogenomics in clinical practice. Per Med. 2015;12:339-47.Qualitative 2015-12
Fujikura K et al. Genetic variation in the human cytochrome P450 supergene family. Pharmacogenet Genomics. 2015;25:584-94.Observation2015-12
Green DJ et al. Pharmacogenomic information in FDA-approved drug labels: application to pediatric patients. Clin Pharmacol Ther. 2015 Dec 22 [Epub ahead of print].Descriptive2015-12
Haga SB et al. Incorporation of pharmacogenetic testing into medication therapy management. Pharmacogenomics. 2015;16:1931-41.Survey2015-11
Rufini S et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction. Pharmacogenomics. 2015;16:1989-2002.Review2015-11
de Leon J et al. What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy? Expert Rev Clin Pharmacol. 2016;9:351-4.Editorial2015-11
Reed EK et al. What works in genomics education: outcomes of an evidenced-based instructional model for community-based physicians. Genet Med. 2015 Nov 19 [Epub ahead of print].Descriptive2015-11
Chang KL et al. Pharmacogenetics: using genetic information to guide drug therapy. Am Fam Physician. 2015;92:588-94.Review2015-10
Brixner D,et al. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ. 2015 Oct 19:1-16 [Epub ahead of print].Prospective Cohort2015-10
Tan-Koi WC et al. Pharmacogenetics through a public health lens: from policy to practice. Pharmacogenet Genomics. 2015;25:518-20.Opinion2015-10
Relling MV et al. Pharmacogenomics in the clinic. Nature. 2015Review2015-10
Millner L et al. A clinical approach to solving discrepancies in therapeutic drug monitoring results for patients on sirolimus or tacrolimus: towards personalized medicine, immunosuppression and pharmacogenomics. Clin Chim Acta. 2015;450:15-8.Case Report2015-10
Johnson JA, Weitzel KW. Advancing pharmacogenomics as a component of precision medicine: How, where and who? Clin Pharmacol Ther. 2015 Oct 6 [Epub ahead of print].Opinion2015-10
Duconge J et al. Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation. Pharmacogenomics. 2015;16:1685-8.
Rafiq M et al. Direct-to-consumer genetic testing: a systematic review of european guidelines, recommendations, and position statements. Genet Test Mol Biomarkers. 2015;19:535-47.Systematic Review2015-10
Vu CL et al. Point-of-care molecular diagnostic devices: an overview. Pharmacogenomics. 2015;16:1399-409Review2015-7
Li-Wan-Po A. Pharmacogenetics begins to deliver on its promises. BMJ. 2015;351:h5042.Commentary2015-09
Peterson JF et al. Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharmacogenomics J. 2015 Aug 11 [Epub ahead of print].Observational2015-08
Meisel SF et al. Explaining, not just predicting, drives interest in personal genomics. Genome Med. 2015;7:74.Observational2015-08
Moaddeb J et al. Community pharmacists' experience with pharmacogenetic testing. J Am Pharm Assoc . 2015;55:587-94.Observational2015-08
He M et al. The development of precision medicine in clinical practice. Clin Transl Med. 2015;4:69.Review2015-08
Shabaruddin FH et al. Economic evaluations of personalized medicine: existing challenges and current developments. Pharmgenomics Pers Med. 2015;8:115-26.Review2015-06
Yip V et al. Pharmacogenetic markers of drug efficacy and toxicity. Clin Pharmacol Ther. 2015 Apr 13 [Epub ahead of print].Review2015-04
Borroni RG. Role of dermatology in pharmacogenomics: drug-induced skin injury. Pharmacogenomics. 2015;16:401–12.Review2015-03
Liu M-Z et al. Pharmacogenomics and herb-drug interactions: merge of future and tradition. Evid Based Complement Alternat Med. 2015;2015:321091.Review2015-03
Lee KC et al. Evaluation of a shared pharmacogenomics curriculum for pharmacy students. Pharmacogenomics. 2015;16:315–22.Survey2015-03
Brennan KS. Clinical implications of pharmacogenetic and microarray testing for advanced practice nurses. J Am Assoc of Nurse Pract. 2015;27:246-55.Review2015-03
Shah RR et al. Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br J Clin Pharmacol. 2015;79:222–40.Review2015-02
Ehmann F et al. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J. 2015;15:201-10.Review2015-02
Barbarino JM et al. PharmGKB summary: very important pharmacogene information for human leukocyte antigen B. Pharmacogenet Genomics. 2015;25:205-21.Review2015-02
Sanderson SC et al. How do students react to analyzing their own genomes in a whole-genome sequencing course?: Outcomes of a longitudinal cohort study. Genet Med. 2015 Jan 29 [Epub ahead of print].Longitudinal cohort study2015-01
Jarrar YB et al. Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy. Drug Metabol Drug Interact. 2014;29:211–20.Review2014-12
Parker LS et al. Ethical considerations regarding classroom use of personal genomic information. J Microbiol Biol Educ. 2014;15:191–6.Perspective2014-12
Vivot A et al. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs. Genet Med. 2014 Dec 18 [Epub ahead of print].Cross-sectional2014-12
Chen Q et al. Human cytochrome p450 and personalized medicine. Adv Exp Med Biol. 2015;827:341–51.Review2014-11
Claudio-Campos K et al. Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. Drug Metabol Drug Interact. 2014 Nov 28 [Epub ahead of print].Review2014-11
Esplin ED et al. Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. Pharmacogenomics. 2014;15:1771–90.Review2014-11
Korf BR et al. Framework for development of physician competencies in genomic medicine: report of the Competencies Working Group of the Inter-Society Coordinating Committee for Physician Education in Genomics. Genet Med. 2014;16:804–9.Descriptive2014-11
Foulkes AC et al. Pharmacogenomics and the resulting impact on psoriasis therapies. Dermatol Clin. 2015;33:149–60.Review2014-11
Alvarellos ML et al. PharmGKB summary: very important pharmacogene information for CYP4F2. Pharmacogenet Genomics. 2015;25:41–7.Review2014-11
Leeder JS et al. Individualizing the use of medications in children: making Goldilocks happy. Clin Pharmacol Ther. 2014;96:304–6.Opinion2014-10
Haga SB et al. Pharmacogenetic information for patients on drug labels. Pharmgenomics Pers Med. 2014a;7:297–305.Descriptive2014-10
Haga SB et al. Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response. Patient Educ Coun. 2014b;97:10–15.Opinion2014-10
Ingelman-Sundberg M. Personalized medicine into the next generation. J Intern Med. 2014 Oct 29 [Epub ahead of print].Commentary2014-10
Quinney SK et al. Is personalized medicine achievable in obstetrics? Semin Perinatol. 2014 Oct 1 [Epub ahead of print].Review2014-10
Daly A. Direct-to-consumer pharmacogenomic testing assessed in a US-based study. J R Coll Physicians Edinb. 2014;44:212–13.Opinion2014-10
Burke W et al. A call for accurate pharmacogenetic labeling: telling it like it is. JAMA Intern Med. 2014 Oct 13 [Epub ahead of print].Editorial2014-09Limitations of pharmacogenomic data in FDA-approved drug labels
Krasniak AE et al. Pharmacogenomics of acetaminophen in pediatric populations: a moving target. Front Genet. 2014;5:314.Review2014-09
Kim T et al. Pharmacogenomic biomarker information in FDA-approved paediatric drug labels. Basic Clin Pharmacol Toxicol. 2014 Oct 28 [Epub ahead of print].Review2014-09
Harrak M et al. Pharmacogenetics and prediction of side effects of drugs. Ann Biol Clin (Paris). 2014;72:405–12.Commentary2014-08 
Teutsch S et al. Utility before business [Commentary]. Genet Med. 2014; [Epub ahead of print]Commentary2014-07 
Lachance K, et al. Opinions, hopes and concerns regarding pharmacogenomics: a comparison of healthy individuals, heart failure patients and heart transplant recipients. Pharmacogenomics J. 2014. [Epub ahead of print] Survey2014-07 
Crawford J et al. The business of genomic testing: a survey of early adopters. Genetics in Medicine. 2014; [Epub ahead of print]. Survey2014-07 
Johansen Taber K et al. Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. Pharmgenomics Pers Med. 2014;7:145-62.Survey2014-07Bridging the pharmacogenomics knowledge gap: Study reveals current needs, strategies
Goulding R et al. Genotype-guided Drug Prescribing: A Systematic Review and Meta-analysis of Randomized Control Trials. Br J Clin Pharmacol. 2014; [Epub ahead of print]Meta-analysis2014-07 
Mattick J. The impact of genomics on the future of medicine and health. Med J Aust. 2014;201:17-20. Perspective2014-07 
Hall M et al. Understanding patient and provider perceptions and expectations of genomic medicine. J Surg Oncol. 2014; [Epub ahead of print]Survey2014-07 
Roberts RL et al. Identification of a novel thiopurine S-methyltransferase allele (TPMT*37). Pharmacogenet Genomics. 2014;24(6):320-3. Case report2014-06 
Baudhuin LM. The FDA and 23andMe: violating the First Amendment or protecting the rights of consumers? Clin Chem. 2014;60:835-7. Opinion2014-06 
Dandara C et al. Cytochrome P450 pharmacogenetics in African populations: implications for public health. Expert Opin Drug Metab Toxicol. 2014; 10:769-85. Review2014-06 
Brownstein CA et al. Misinterpretation of TPMT by a DTC genetic testing company. Clinical Pharmacology and Therapeutics. 2014 [Epub ahead of print]Case Report2014-05 
Meyers DA et al. Asthma genetics and personalised medicine. Lancet Respir Med. 2014;2:405-15.Review2014-05 
Vayena E. Direct-to-consumer genomics on the scales of autonomy. J Med Ethics. 2014 [Epub ahead of print]Perspective2014-05 
Yang Y et al. Pharmacogenetics in Jewish populations. Drug Metabol Drug Interact. 2014; [Epub ahead of print].Review2014-05 
Hatz MH et al. Is Individualized Medicine More Cost-Effective? A Systematic Review. PharmacoEconomics. 2014; [Epub ahead of print].Systematic Review2014-05 
Korbel L et al. Clinically Relevant Pharmacogenomic Testing in Pediatric Practice. Clin Pediatr (Phila). 2014;53:831-8.Review2014-05
Verbeurgt P et al. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics. 2014:15(5):655-65. Case series2014-04 
Awada Z et al. Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program. Pharmacogenomics. 2014;15:845–56.Review2014-04
Farrell CL. Application of genomic principles to pharmacotherapy of cancer. Am J Pharm Educ. 2014;78(3):55.  Survey2014-04 
Zhang SC et al. Public Perceptions of Pharmacogenetics. Pediatrics. 2014. Survey2014-04